Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: Encouraging results of a phase II study

Keyphrases

• Tumor Necrosis Factor-α 100%
• Phase II Study 100%
• Hyperthermia 100%
• Locally Advanced Cancer 100%
• Pelvic Perfusion 100%
• Isolated Pelvic Perfusion 100%
• Melphalan 60%
• Magnetic Resonance Imaging 60%
• Technetium-99m 40%
• Technetium 40%
• Chemotherapy 20%
• Survival Rate 20%
• Pharmacokinetic Study 20%
• Median Overall Survival 20%
• Recurrence Rate 20%
• Carcinoma 20%
• Melanoma 20%
• Sarcoma 20%
• Necrosis 20%
• Local Recurrence 20%
• Metastatic Recurrence 20%
• Disease-free Survival 20%
• Complete Response Rate 20%
• Exenteration 20%
• Tourniquet 20%
• Locally Advanced 20%
• Groin 20%
• Endocrine Tumors 20%
• Pelvic Cancer 20%
• Exarticulation 20%
• Thigh 20%
• Historical Data 20%
• Limb Perfusion 20%
• Human Serum Albumin 20%
• Positive Pressure Suit 20%

Medicine and Dentistry

• Tumor Necrosis Factor 100%
• Pelvis 100%
• Advanced Cancer 100%
• Magnetic Resonance Imaging 37%
• Melphalan 37%
• Technetium-99 25%
• Survival Rate 12%
• Overall Survival 12%
• Carcinoma 12%
• Recurrence Risk 12%
• Necrosis 12%
• Pharmacokinetics 12%
• Disease Free Survival 12%
• Exenteration 12%
• Limb Perfusion 12%
• Endocrine Tumor 12%
• Pelvis Cancer 12%
• Disarticulation 12%
• Human Serum Albumin 12%
• Chemotherapy 12%
• Melanoma 12%
• Connective Tissue Cancer 12%
• Thigh 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Necrosis Factor 100%
• Advanced Cancer 100%
• Melphalan 60%
• Technetium 99m 40%
• Overall Survival 20%
• Chemotherapy 20%
• Survival Rate 20%
• Melanoma 20%
• Carcinoma 20%
• Disease Free Survival 20%
• Necrosis 20%
• Limb Perfusion 20%
• Recurrence Risk 20%
• Endocrine Tumor 20%
• Human Serum Albumin 20%
• Pelvis Cancer 20%
• Pharmacokinetics 20%
• Connective Tissue Cancer 20%